INTRODUCTION
a-Thrombin binds to a wide variety of cell types and evokes numerous responses, most of which are associated with cellular activation [1] [2] [3] . A thrombin receptor has been cloned and sequenced using cDNA from different cell types; in each case the same protein has been identified [1, [3] [4] [5] . The cloned thrombin receptor has an apparent protein mass of 47 kDa, is significantly N-glycosylated [5] , has seven transmembrane domains, and is coupled via G-proteins to a variety of signal transduction systems [1, 5] . Comparison of the cDNA sequences of the human and rat thrombin receptors indicates that the receptors are 78 similar at the amino acid level [6] .
Like thrombin, plasmin associates with a specific and saturable system of binding sites in a variety of cell types [7] . The affinity of the plasmin-binding interaction is low (0.1-1.0 ,uM) but the cellular binding capacity is typically high (105-107 sites per cell). Plasmin and the zymogen [Glu1]plasminogen bind to the same cellular sites; the interaction is dependent upon a series of kringle domains which express lysine-binding sites [8] .
The molecular nature of cellular plasmin(ogen)-binding sites remains incompletely understood and, in fact, a variety of plasma membrane macromolecules may contribute to the total cellular plasminogen-binding capacity. Nevertheless, sequestration and concentration of plasminogen at the cell surface is important for a variety of proteinase-mediated processes that involve cellular migration or tissue remodelling [9] . While associated with the cell surface, plasmin demonstrates significant proteolytic activity towards a variety of substrates a2-antiplasmin and a2-macroglobulin [10] . Therefore, bound plasmin may selectively alter substrates in the microenvironment of the cell surface, including integral plasma membrane proteins. Although the effects of plasmin and plasminogen on cellular -signal transduction are largely uncharacterized, it was recently reported that plasmin binding to human umbilical vein endothelial cells inhibits protein kinase activity [11] .
Platelet-activating factor (PAF) is produced by two independent enzymic pathways involving either structural modification of a membrane lipid or de novo synthesis from an O-alkyl analogue of a lysophosphatidic acid [12] . As a potent lipid mediator of cellular function, PAF induces a wide range of biological responses including activation of protein kinases, and stimulation of arachidonic acid and phosphoinositide metabolism [12] [13] [14] [15] . PAF interacts through the sn-2 position of its acetyl moiety with a surface membrane receptor that is proteinase sensitive and appears to be coupled to a G-protein [12, [14] [15] [16] . In the brain, PAF functions in ischaemic and traumatic injury, exerting cytotoxic effects on neuronal cells, causing vasoconstriction and modulating the blood-brain barrier [17, 18] .
Previous studies have demonstrated that rat C6 glioma cells have specific cellular binding sites for plasminogen and plasmin [19] . Furthermore, these cells respond to thrombin with transitions of free intracellular Ca2+ concentration ([Ca2+] i) [20] and to PAF with increased astrocytic differentiation [21] [Glu1]Plasminogen was purified from fresh frozen human plasma as previously described [22] and dialysed against 1O mM Hepes/50 mM sodium acetate, pH 7.4. Plasminogen (3.0-5.0/uM) was activated with low-molecular-mass urokinase (20 nM) (Calbiochem) for 15 min at 37 'C. The extent of activation was determined by active-site titration with pnitrophenyl p-guanidinobenzoate [23] or by the rate of hydrolysis of the plasmin-specific substrate, H-D-valyl-L-leucyl-L-lysine-pnitroanilide hydrochloride (Kabi Vitrum), using previously determined kinetic parameters [24] . Di-isopropylphosphoryl plasmin (DIP-plasmin) was prepared by incubating plasmin twice with 10 mM di-isopropylphosphorofluoridate (DFP; Sigma) for 1 h at 22 'C. Excess DFP was removed by dialysis against 20 mM sodium phosphate/ 154 mM NaCl, pH 7.4. Residual plasmin activity in DIP-plasmin preparations was always less than 0.1 % as determined by S-2251 hydrolysis.
The thrombin-receptor tethered ligand peptide, SFLLRN-PNDKYEPFC, was synthesized by the Protein and Nucleic Acids Core Laboratory at the University of Virginia. The structure was confirmed by amino acid analysis and mass spectroscopy. The first five or six residues of this peptide constitute the essential sequence for thrombin-receptor activation [25, 26] . The cells were passaged after reaching 900% confluency (every 4-5 days) and plated at an initial density of (6) (7) (8) [27] was determined by treating the cells with 2.0 ,IM ionomycin (Molecular Probes). Rmin [27] was determined by treating cells with ionomycin followed by 10 22 'C. Leakage of the free acid form of Indo-l from the cells was negligible.
Thrombin evoked an increase in free [Ca2+] , and the magnitude of the effect was thrombin-concentration dependent. The maximum amplitude of response was observed with 2-4 nM thrombin (Figure 1) (8 nM) by 500% (Figure 4 ) and to the thrombin-agonist peptide (20 ,ug/ml) by 400% ( Figure 5 ). When the concentration of thrombin was increased to 40 nM, the response in plasminpretreated cells was only slightly improved (less than 10%). Similarly, increasing the concentration of agonist peptide to 60 ,ug/ml improved the response by only 60% (compared with control cells which were not pretreated with plasmin). The latency and duration of the response to thrombin and agonist peptide were essentially unchanged in plasmin-treated cells. C6 cells that were pretreated with DIP-plasmin (Figure 4) [1, 3, 5] .
Thrombin-receptor activation is initiated after proteolytic cleavage of the Arg41-Ser42 peptide bond [34] . The new Nin at 22 0C significantly terminus then functions as a tethered peptide ligand, binding to fist peptide. Stopped-flow a separate site in the receptor [26, 35, 36] . In this investigation, we of 1000 points. 20 tg/ml demonstrated that plasmin modifies the ability of C6 cells to treatment respond to thrombin. Since plasminogen and DIP-plasmin had no effect, the most likely mechanism whereby plasmin modifies the thrombin response is direct proteolytic modification of the thrombin receptor. One explanation for our results is that plasmin slowly cleaves the same peptide bond that thrombin cleaves (Arg4l-Ser42), causing receptor inactivation/internalization [37, 38] . Ishii et al. [37] [37, 38] .
The effects of plasmin on platelet responses to a variety of agonists including thrombin are complex and plasmin-concentration dependent [39, 40] . The platelet inhibitory activity of plasmin may be the result of a generalized process: blocking the mobilization of arachidonic acid from membrane phospholipid PAF16 ( Figure 6) pools [40] . The complete preservation of the PAF response in -concentration de- [31, 45] . In addition, thrombin-stimulated astrocytes secrete increased amounts of nerve growth factor-f [46] and endothelin [47] . Therefore the selective effects of plasmin in modulating the astroglial response to thrombin may be physiologically significant during both development and brain injury. Thrombin and plasmin play opposite roles in haemostasis and the present studies suggest that an analogous relationship may exist in cell function.
